These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27460078)

  • 1. VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT through the IGF1R-PI3K pathway.
    Yamaguchi R; Harada H; Hirota K
    Tumour Biol; 2016 Oct; 37(10):13295-13306. PubMed ID: 27460078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
    Choudhary GS; Al-Harbi S; Mazumder S; Hill BT; Smith MR; Bodo J; Hsi ED; Almasan A
    Cell Death Dis; 2015 Jan; 6(1):e1593. PubMed ID: 25590803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R; Janssen E; Perkins G; Ellisman M; Kitada S; Reed JC
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY
    Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 13-acetoxysarcocrassolide induces apoptosis on human gastric carcinoma cells through mitochondria-related apoptotic pathways: p38/JNK activation and PI3K/AKT suppression.
    Su CC; Chen JY; Din ZH; Su JH; Yang ZY; Chen YJ; Wang RY; Wu YJ
    Mar Drugs; 2014 Oct; 12(10):5295-315. PubMed ID: 25342459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Blancher C; Moore JW; Robertson N; Harris AL
    Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; Pétigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
    He X; Wang J; Messing EM; Wu G
    Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
    Jokinen E; Koivunen JP
    Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of PI3K/Akt signaling by synthetic bichalcone analog TSWU-CD4 induces ER stress- and Bax/Bak-mediated apoptosis of cancer cells.
    Lin ML; Chen SS; Huang RY; Lu YC; Liao YR; Reddy MV; Lee CC; Wu TS
    Apoptosis; 2014 Nov; 19(11):1637-53. PubMed ID: 25183449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mcl-1 expression and JNK activation induces a threshold for apoptosis in Bcl-xL-overexpressing hematopoietic cells.
    Zhang Y; Li X; Tan S; Liu X; Zhao X; Yuan Z; Nie C
    Oncotarget; 2017 Feb; 8(7):11042-11052. PubMed ID: 28038464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
    Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells.
    Chowdhury P; Perera D; Powell RT; Talley T; Tripathi DN; Park YS; Mancini MA; Davies P; Stephan C; Coarfa C; Dere R
    Sci Rep; 2021 May; 11(1):10461. PubMed ID: 34002003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin restores ABT-737-mediated apoptosis in human renal carcinoma cells.
    Ou YC; Li JR; Wang JD; Chen WY; Kuan YH; Yang CP; Liao SL; Lu HC; Chen CJ
    Biochem Biophys Res Commun; 2018 Jul; 502(2):187-193. PubMed ID: 29792865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.
    Pareja F; Macleod D; Shu C; Crary JF; Canoll PD; Ross AH; Siegelin MD
    Mol Cancer Res; 2014 Jul; 12(7):987-1001. PubMed ID: 24757258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.